(Q41318585)

English

Interferon-α-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil

scientific article published on August 1, 1995

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Interferon-α-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil (English)

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

cancer cell line

1 reference

based on heuristic

inferred from title

author name string

T. Imai

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7634247

25 June 2024

A. Katagiri

2

0000-0001-8057-1177

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7634247

25 June 2024

K. Saito

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7634247

25 June 2024

Y. Tomita

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7634247

25 June 2024

language of work or name

0 references

publication date

1 August 1995

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:030438359503849R?httpAccept=text/xml

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

https://api.elsevier.com/content/article/PII:030438359503849R?httpAccept=text/plain

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

191-197

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Treatment of Advanced Renal Cell Carcinoma—Traditional Methods and Innovative Approaches

1

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

The role of radiation therapy in the management of carcinoma of the kidney

2

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

The natural history of metastatic renal cell carcinoma: a computer analysis

3

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Interferon treatment of renal cell carcinoma. Current status and future prospects

5

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

6

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

7

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial

8

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Induction and kinetics of natural killer cells in humans following interferon therapy

10

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells

12

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle

13

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

14

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects

15

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha

16

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.

17

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

19

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

[Interferon-induced protection of renal cell cancer cell lines to lymphokine-activated killer (LAK) cells and effect of acid treatment on their susceptibility. Its relevance to expression of major histocompatibility complex class I antigens on tumor

21

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Interferon effects upon fluorouracil metabolism by HL-60 cells

22

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Functional evidence that intercellular adhesion molecule-1 (icam-1) is a ligand for lfa-1d-ependent adhesion in t cell-mediated cytotoxicity

24

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis

25

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

ICAM- melanoma cells are relatively resistant to CD3-mediated T-cell lysis

26

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

27

1 reference

10.1016/0304-3835(95)03849-R

https://api.crossref.org/works/10.1016/0304-3835(95)03849-R

25 June 2024

Identifiers

10.1016/0304-3835(95)03849-R

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41318585&oldid=2188506979"